ADC	Antibody–drug conjugates
NSCLC	Non-small cell lung cancer
HER2	Human epidermal growth factor receptor 2
HER3	Human epidermal growth factor receptor 3
TROP2	Trophoblast cell surface antigen 2
C-MET	Mesenchymal–epithelial transition factor
CEACAM5	Carcinoembryonic antigen-related cell adhesion molecule 5
ICI	Immune checkpoint inhibitor
T-DM1	Trastuzumab emtansine
T-DXd	Trastuzumab deruxtecan
IHC	Immunohistochemistry
DAR	Drug-to-antibody ratio
NK	Natural killer cell
ERBB2	Erb-b2 receptor tyrosine kinase 2
EGFR	Epidermal growth factor receptor
HER1	Human epidermal growth factor receptor 1
HER4	Human epidermal growth factor receptor 4
AGA	Actionable genomic alteration
TKI	Tyrosine kinase inhibitor
NGS	Next-generation sequencing
ORR	Objective response rate
CR	Complete response
PR	Partial response
mPFS	Median progression-free survival
CI	Confidence interval
mOS	Median overall survival
CNS	Central nervous system
DCR	Disease control rate
mDOR	Median duration of response
AEs	Adverse event
TRAE	Treatment-related adverse effect
ILD	Interstitial Lung Disease
DFS	Disease-free survival
ALK	Anaplastic Lymphoma Kinase
ROS1	Proto-oncogene tyrosine-protein kinase
NTRK	Neurotrophic tyrosine receptor kinase
BRAF	V-raf murine sarcoma viral oncogene homolog B1
MET	MET proto-oncogene receptor tyrosine kinase
RET	Rearranged during transfection
CT	Chemotherapy
RCT	Randomized controlled trial
HR	Hazard ratio
PD-L1	Programmed Cell Death Ligand 1
UGT1A1	UDP glucuronosyltransferase family 1 member A1
SG	Sacituzumab govitecan
PI3K	Phosphatidylinositol-3 kinase
PBC	Platinum-based chemotherapy
mTOR	Mammalian target of rapamycin
ERK	Extracellular signal-regulated kinases
RP2D	Recommended dose for phase 2
LD	Loading dose
IDMC	Independent Data Monitoring Committee
ctDNA	Circulating tumor DNA